F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comAlembic Pharmaceuticals Ltd, a leading Indian pharmaceutical company, has been a key player in the healthcare and life sciences industry for decades. Known for its focus on innovation, high-quality generics, and global presence, Alembic Pharma continues to strengthen its market position both in India and internationally.
In this blog, we’ll explore Alembic Pharmaceuticals Ltd’s share price target from 2025 to 2030, analyze its financial indicators, and provide insights for long-term investors.
| Detail | Value |
|---|---|
| Open | ₹929.95 |
| Previous Close | ₹924.20 |
| Day’s High | ₹998.00 |
| Day’s Low | ₹927.90 |
| VWAP | ₹976.90 |
| Volume | 1,155,390 |
| Value (Lacs) | ₹11,215.95 |
| Market Capitalization | ₹19,081 Cr |
| Beta (Volatility) | 0.61 |
| Face Value | ₹2 |
| Book Value Per Share | ₹264.09 |
| Dividend Yield | 1.13% |
| 52-Week High | ₹1,152.00 |
| 52-Week Low | ₹725.20 |
| All-Time High | ₹1,303.90 |
| All-Time Low | ₹31.00 |
| UC Limit | ₹1,109.00 |
| LC Limit | ₹739.40 |
| 20D Avg Volume | 68,681 |
| 20D Avg Delivery (%) | 47.74% |
Founded in 1907, Alembic Pharmaceuticals Ltd is one of India’s oldest and most trusted pharmaceutical companies. The company is engaged in manufacturing and marketing branded and generic formulations, active pharmaceutical ingredients (APIs), and specialty medicines. Alembic has a strong presence across India, the U.S., and emerging markets.
Over 100+ years of industry expertise
Diversified product portfolio in cardiology, oncology, and anti-infectives
Strong R&D foundation with multiple FDA-approved facilities
Global presence in more than 75 countries
Stable financial performance and consistent dividend payout
| Investor Type | Holding (%) |
|---|---|
| Promoters | 69.74% |
| Retail & Others | 9.92% |
| Mutual Funds | 8.55% |
| Other Domestic Institutions | 7.75% |
| Foreign Institutions | 4.05% |
A high promoter holding of nearly 70% reflects strong internal confidence in the company’s long-term prospects. Mutual funds and domestic institutions also maintain a steady stake, indicating trust from institutional investors.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 940 | 1,020 |
| 2026 | 1,080 | 1,160 |
| 2027 | 1,200 | 1,320 |
| 2028 | 1,340 | 1,480 |
| 2029 | 1,500 | 1,640 |
| 2030 | 1,680 | 1,850 |
These projections are based on Alembic’s historical performance, revenue growth trends, product pipeline, and global demand for pharmaceutical products.
Alembic Pharma is expected to maintain stability in FY2025 with moderate growth driven by domestic formulations and improved exports.
Why?
Steady demand in India’s generic drug market
Healthy R&D expenditure for new product launches
Increased operating margin due to efficient cost control
Investment Advice:
Investors can consider accumulating shares on dips for long-term growth.
In 2026, Alembic may see stronger growth from its API and U.S. generics business.
Why?
Rising exports to the U.S. and Europe
Strong pipeline of ANDA approvals
Better realization in specialty products
Investment Advice:
Hold or add positions as the company’s international business expands.
The company is expected to post higher earnings per share and enhanced profitability by 2027.
Why?
Focus on high-margin specialty therapies
Growth in chronic disease portfolio
Strategic alliances in emerging markets
Investment Advice:
Good time to reinvest dividends and continue holding for the long term.
By 2028, Alembic could benefit from scale expansion and new drug approvals.
Why?
Expansion of R&D infrastructure
Entry into biologics and advanced formulations
Increasing healthcare spending across India
Investment Advice:
Long-term investors can expect steady capital appreciation with consistent dividend returns.
Alembic’s continued innovation and export performance can drive the next growth phase.
Why?
Strengthened U.S. FDA compliance track record
Product launches in niche therapeutic segments
Strong balance sheet and zero major debt concerns
Investment Advice:
Ideal for mid-to-long term investors seeking stability and moderate returns.
By 2030, Alembic Pharma may emerge as one of India’s top 10 global healthcare exporters.
Why?
Diversified global presence
Consistent EPS and profit growth
Expansion into digital healthcare and AI-driven research
Investment Advice:
A solid buy-and-hold stock for investors targeting long-term wealth creation.
Yes, Alembic Pharmaceuticals is a fundamentally strong and stable stock backed by experienced management and consistent earnings.
Strong promoter confidence and institutional participation
Steady dividend yield of 1.13%
Low beta (0.61) — indicating reduced volatility
Expanding international market footprint
Regulatory challenges in the U.S. or EU markets
Price control policies in India’s pharma sector
Currency fluctuations impacting export margins
Alembic Pharmaceuticals Ltd continues to strengthen its position in the pharmaceutical industry with a focus on innovation, global expansion, and value-driven growth. With strong fundamentals, high promoter holding, and increasing R&D investments, Alembic looks well-positioned for long-term success.
At the current price level of around ₹929.95, analysts believe the stock could reach ₹1,850 by 2030 if growth momentum continues. For investors seeking a balance of growth and stability in the healthcare sector, Alembic Pharma is a promising long-term pick.
1. What is the current share price of Alembic Pharmaceuticals?
As of November 2025, Alembic Pharma’s share price is around ₹929.95.
2. What is the 2025 share price target for Alembic Pharmaceuticals?
The expected share price target for 2025 ranges between ₹940 and ₹1,020.
3. Is Alembic Pharmaceuticals a good long-term investment?
Yes, it has strong fundamentals, a high promoter stake, and consistent dividends.
4. What is Alembic Pharmaceuticals’ 2030 share price target?
By 2030, Alembic Pharma’s share price could range from ₹1,680 to ₹1,850 based on current growth trends.
5. What is the dividend yield of Alembic Pharmaceuticals?
The company offers a dividend yield of around 1.13%.
6. What are the major risk factors for Alembic Pharmaceuticals?
Regulatory challenges, market competition, and currency fluctuations.
7. What is Alembic Pharmaceuticals’ market capitalization?
The market cap stands at approximately ₹19,081 crore.
8. How much is the promoter holding in Alembic Pharmaceuticals?
Promoters hold about 69.74% of the total shares.
9. What is Alembic Pharma’s all-time high share price?
The all-time high is ₹1,303.90.
10. Should I buy Alembic Pharma shares now?
If you have a medium-to-long-term horizon (3–5 years), Alembic Pharma is a fundamentally sound pick.
Disclaimer: This article is for educational purposes only and should not be considered financial advice. Always consult a certified financial advisor before making investment decisions.
Register & Login